Hoping to increase sales in China’s rapidly growing pharmaceutical market, Eli Lilly and Co. is charging ahead
with
plans to invest $100 million in venture capital in the region over the next several years.
Dr. Francis Price Jr. has brought hundreds of eye surgeons to Indianapolis to train them in how to use
a new cornea transplant technique that has swept the ophthalmology field—DSEK, which stands
for Descemet’s stripping endothelial keratoplasty.
The St. Francis hospital system and Anthem Blue Cross and Blue Shield of Indiana are haggling over insurance reimbursement
costs. The original demand of Sisters of St. Francis Health Services Inc. would have increased reimbursement amounts $80 million
over three years, Rick Rhodes, an Anthem regional vice president, wrote in an Oct. 30 letter to employers covered by Anthem.
The increase would mean $12 million more in out-of-pocket costs to Anthem customers. But St. Francis claims its request for
an increase only brings it in line with what other hospitals are getting.
Eli Lilly and Co. has written a $6.5 billion IOU to acquire the cancer drugs of ImClone Systems Inc. Cancer drugs are now
the best-selling class of drugs in the world and one of the fastest growing.
Eli Lilly and Co.’s unorthodox efforts to develop new treatments for Alzheimer’s disease–if successful–could usher in
a new approach to drug development. The Indianapolis-based pharmaceutical company announced that a New York
hedge fund, TPG-Axon Capital, will invest up to $325 million to help cover the exorbitant development costs
of two experimental compounds to treat Alzheimer’s disease.
Eli Lilly and Co. hopes to extend the life of its best-seller Zyprexa with a potentially lucrative, long-acting form of the antipsychotic drug. But first, the Indianapolis-based drugmaker must win over a panel of medical experts convened by the U.S. Food and Drug Administration on Feb. 6.
A new leader will guide the city’s largest company in 2008, with some of the biggest challenges in its history on the horizon.
Eli Lilly and Co. announced Dec. 18 that CEO Sidney Taurel will step down March 31 and will be replaced by President John
C. Lechleiter, who has been the heir apparent for more than two years.
When Eli Lilly and Co. CEO Sidney Taurel announced his retirement Dec. 18, he said he was leaving the company in good shape.
And he can cite plenty of evidence to support him. But when Taurel steps down as CEO March 31, he also will leave a legacy
of a languishing stock price and some costly mistakes that some think could have been avoided. “The facts are the facts; I
guess you can’t ignore it. The stock price has been…
John C. Lechleiter, whom Eli Lilly and Co.’s board voted to replace Sidney Taurel as CEO, is known for getting things done
and yet also for being good at analysis and relating to people under him. Taurel will step down at the end of March but remain
chairman until the end of 2008.
Eli Lilly and Co. will shrink itself with “great intensity” over the next few years, in part by
outsourcing. For other local life sciences firms, that’s a fat pitch for new business. But it’s not clear if non-Lilly firms
can grow fast enough to offset the jobs and wages Indianapolis will lose from Lilly.
There’s a $2 billion hole in Eli Lilly and Co.’s future. That’s roughly how much pretax profit Lilly derives each year from
its best-seller, Zyprexa, according to calculations by IBJ. And it’s how much black ink will start running off Lilly’s books
once Zyprexa’s U.S. and European patents expire in 2011.
